Autonomix Medical Inc. (NASDAQ: AMIX) announced on Aug. 4, 2026, that it has been issued U.S. Patent No. 12,433,670, significantly expanding its intellectual property protection for precision neuromodulation technologies. The patent, titled "Systems and Methods for Treating Cancer and/or Augmenting Organ Function," covers systems designed to sense, map, and selectively target nerves associated with tumors, cancer-related pain, and organ function. This development reinforces the company’s strategy to build a comprehensive IP portfolio spanning precision nerve sensing and targeted therapy across multiple therapeutic applications.

The newly issued patent protects minimally invasive catheter-based microsurgical tools capable of recording neural signals and delivering energy or therapeutic agents to block or modulate identified nerves. The technology enables the mapping of electrophysiological activity associated with tumors or metastatic cells, allowing clinicians to use this data to guide targeted treatment. By selectively blocking tumor-associated nerves, the system aims to address cancer-related pain while minimizing unintended effects on surrounding tissue.

Technology Capabilities and Applications

The patent describes several key technological functions intended to advance the treatment of diseases involving the autonomic nervous system:

The technology is applicable across a range of solid tumors, including pancreatic, prostate, breast, colorectal, liver, ovarian, and bone cancers. Autonomix is initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition characterized by debilitating pain and a lack of reliable solutions.

Strategic IP Expansion

Brad Hauser, Chief Executive Officer of Autonomix Medical, stated that the patent represents a meaningful expansion of the company’s intellectual property portfolio. He emphasized that the company’s strategy is to build a comprehensive IP base spanning precision nerve sensing, physiologic assessment, and targeted neuromodulation. This latest patent strengthens the foundation supporting that strategy while reinforcing the versatility and long-term potential of the platform.

The new patent builds upon Autonomix’s existing IP portfolio, which includes previously issued patents covering autonomic nervous system assessment, neural sensing, treatment guidance, and transvascular neuromodulation technologies. Together, these patents support the development of differentiated technologies designed to precisely identify and target disease-associated nerves. The company’s platform system includes a catheter-based microchip sensing array that may detect and differentiate neural signals with greater sensitivity than conventional technologies.

What the Numbers Show

While no financial figures were disclosed in the announcement, the issuance of U.S. Patent No. 12,433,670 marks a tangible milestone in Autonomix’s non-financial asset accumulation. The expansion of IP protection into specific oncology indications—particularly pancreatic cancer pain—signals a strategic focus on high-unmet-need areas where current treatments are limited. The broad scope of the patent, covering both cancer-related pain and general organ function modulation, suggests the company intends to leverage its core sensing technology across multiple distinct therapeutic markets rather than relying on a single indication.

Autonomix Medical Inc. (NASDAQ: AMIX) shares triggered a circuit breaker halt to the upside, surging 116.73% to $5.97 in extended trading. The dramatic rally follows the announcement of positive preclinical results showing the company’s neural sensing platform can detect changes in renal nerve activity during ablation. This development marks a significant step toward a precise, data-driven treatment for resistant hypertension, reversing earlier intraday losses.

Trading volume exploded to 10.60 million shares, more than 24 times the average daily volume of 439,140 shares. The stock had previously closed at $2.75 before the news broke. Short interest remains at 3.1%. The Relative Strength Index (RSI) was at 18.21 prior to the surge, indicating oversold conditions that likely fueled the short squeeze and aggressive buying.

Financial Position and Share Structure

The company holds a cash balance of approximately $5.1 million as of Tuesday, reflecting proceeds from a warrant inducement dated July 13. There are 971,043 shares outstanding. Autonomix Medical registered 857,462 shares for resale upon the exercise of Series D common stock purchase warrants with an exercise price of $5.75 per share. Full cash exercise could generate up to $4.9 million in gross proceeds.

Technical Context and Performance

Despite the sharp recovery, Autonomix Medical has declined 89.69% over the past 12 months. The stock trades near its 52-week low of $2.44, far below its 52-week high of $32.55. Benzinga’s Edge Stock Rankings indicate a negative price trend across all time frames. Analysts warn that despite the recent catalyst, the stock faces ongoing pressure due to its weak long-term position.

What the Numbers Show

The disparity between the warrant exercise price of $5.75 and the previous closing price of $2.75 highlights significant dilution risk if warrants are exercised. However, the current surge to $5.97 places the stock above the exercise price, potentially incentivizing warrant holders to exercise for cash rather than net shares, thereby strengthening the company’s liquidity position relative to its $5.1 million cash balance.